Regardless of LVEF, semaglutide improves exercise capacity and physical limitations in patients with HFpEF who exhibit an obesity phenotype.

Published Date: 20 Oct 2023

Patients with heart failure who exhibit an obesity phenotype may benefit from treatment with semaglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New surgical method shows promising results for cervical cancer treatment

2.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

Can Prior Authorization Be Better With Artificial Intelligence?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot